UBS Group started coverage on shares of 10x Genomics (NASDAQ:TXG – Get Rating) in a research report released on Thursday, The Fly reports. The brokerage issued a neutral rating and a $50.00 price target on the stock.
Several other analysts have also commented on TXG. The Goldman Sachs Group dropped their price target on shares of 10x Genomics from $35.00 to $25.00 and set a sell rating on the stock in a research report on Thursday, October 13th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of 10x Genomics in a research note on Tuesday, December 13th. They set a buy rating and a $50.00 target price on the stock. Morgan Stanley lowered their target price on shares of 10x Genomics from $70.00 to $64.00 and set an overweight rating on the stock in a research note on Friday, November 4th. Finally, JPMorgan Chase & Co. lowered their target price on shares of 10x Genomics from $65.00 to $55.00 in a research note on Thursday, November 3rd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of Hold and an average target price of $50.90.
Get
10x Genomics alerts:
10x Genomics Stock Down 3.6 %
Shares of TXG traded down $1.79 during trading hours on Thursday, reaching $47.93. 111,934 shares of the company traded hands, compared to its average volume of 1,146,258. 10x Genomics has a 12-month low of $23.81 and a 12-month high of $99.14. The stock's fifty day moving average price is $39.36 and its 200 day moving average price is $35.90.
10x Genomics (NASDAQ:TXG – Get Rating) last announced its earnings results on Wednesday, November 2nd. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. 10x Genomics had a negative net
margin of 33.20% and a negative return on equity of 21.01%. The business had revenue of $131.10 million during the quarter, compared to the consensus estimate of $129.13 million. During the same period in the previous year, the company posted ($0.15) earnings per share. The firm's revenue was up 4.6% on a year-over-year basis. Equities research analysts expect that 10x Genomics will post -1.6 earnings per share for the current year.
Insiders Place Their Bets
In other news, insider Benjamin J. Hindson sold 2,361 shares of the firm's stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $34.07, for a total value of $80,439.27. Following the completion of the transaction, the insider now owns 217,713 shares in the company, valued at $7,417,481.91. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, insider Benjamin J. Hindson sold 2,361 shares of 10x Genomics stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $34.07, for a total value of $80,439.27. Following the transaction, the insider now directly owns 217,713 shares of the company's stock, valued at approximately $7,417,481.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Justin J. Mcanear sold 1,626 shares of 10x Genomics stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $34.07, for a total value of $55,397.82. Following the sale, the chief financial officer now owns 76,764 shares in the company, valued at $2,615,349.48. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,663 shares of company stock worth $227,008. 11.08% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On 10x Genomics
A number of institutional investors and hedge funds have recently modified their holdings of TXG. Wipfli Financial Advisors LLC acquired a new position in 10x Genomics during the third quarter valued at $26,000. First Horizon Advisors Inc. boosted its stake in 10x Genomics by 14,780.0% during the 2nd quarter. First Horizon Advisors Inc. now owns 744 shares of the company's stock valued at $33,000 after purchasing an additional 739 shares during the period. Atlas Capital Advisors LLC boosted its stake in 10x Genomics by 45.5% during the 3rd quarter. Atlas Capital Advisors LLC now owns 1,360 shares of the company's stock valued at $39,000 after purchasing an additional 425 shares during the period. CWM LLC raised its holdings in 10x Genomics by 48.9% in the 4th quarter. CWM LLC now owns 1,185 shares of the company's stock valued at $43,000 after acquiring an additional 389 shares in the last quarter. Finally, Rockefeller Capital Management L.P. raised its holdings in 10x Genomics by 95.2% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 2,875 shares of the company's stock valued at $81,000 after acquiring an additional 1,402 shares in the last quarter. 74.34% of the stock is owned by institutional investors and hedge funds.
10x Genomics Company Profile
(Get Rating)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.
See Also
- Get a free copy of the StockNews.com research report on 10x Genomics (TXG)
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
- Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
- Bright Green Corporation Future May be Getting Brighter
- Microsoft Fast Integrating AI Into Enterprise & Healthcare Suites
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
